As additional clinical trial and real-world data on T-DXd emerge, particularly its role in treating HER2-low breast cancer, establishing a UAE-specific consensus among oncologists on practical treatment considerations and management of associated toxic effects can foster knowledge sharing and informed decision-making. This evidence concerns the gene ERBB2 and breast carcinoma.